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Abstract
In order to detect serum antibodies against clinically important Old and New World hantaviruses simultaneously,
multiparametric indirect immunofluorescence assays (IFAs) based on biochip mosaics were developed. Each of the mosaic
substrates consisted of cells infected with one of the virus types Hantaan (HTNV), Puumala (PUUV), Seoul (SEOV), Saaremaa
(SAAV), Dobrava (DOBV), Sin Nombre (SNV) or Andes (ANDV). For assay evaluation, serum IgG and IgM antibodies were
analyzed using 184 laboratory-confirmed hantavirus-positive sera collected at six diagnostic centers from patients actively
or previously infected with the following hantavirus serotypes: PUUV (Finland, n = 97); SEOV (China, n = 5); DOBV (Romania,
n = 7); SNV (Canada, n = 23); ANDV (Argentina and Chile, n = 52). The control panel comprised 89 sera from healthy blood
donors. According to the reference tests, all 184 patient samples were seropositive for hantavirus-specific IgG (n = 177; 96%)
and/or IgM (n = 131; 72%), while all control samples were tested negative. In the multiparametric IFA applied in this study,
183 (99%) of the patient sera were IgG and 131 (71%) IgM positive (accordance with the reference tests: IgG, 96%; IgM,
93%). Overall IFA sensitivity for combined IgG and IgM analysis amounted to 100% for all serotypes, except for SNV (96%).
Of the 89 control sera, 2 (2%) showed IgG reactivity against the HTNV substrate, but not against any other hantavirus. Due
to the high cross-reactivity of hantaviral nucleocapsid proteins, endpoint titrations were conducted, allowing serotype
determination in .90% of PUUV- and ANDV-infected patients. Thus, multiparametric IFA enables highly sensitive and
specific serological diagnosis of hantavirus infections and can be used to differentiate PUUV and ANDV infection from
infections with Murinae-borne hantaviruses (e.g. DOBV and SEOV).
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Introduction
Hantaviruses are enveloped and negative-sense single-stranded
RNA viruses of the Bunyaviridae family. The hantavirus genome
consists of three segments (L, M, and S), coding for the viral RNA
polymerase (L protein), glycoproteins (Gn and Gc) and the
nucleocapsid (N) protein, respectively [1–5]. The majority of
hantaviruses are etiologic agents of either hemorrhagic fever with
renal syndrome (HFRS) or hantavirus cardiopulmonary syndrome
(HCPS). The number of hantavirus infections is increasing, as
reflected by a very recent outbreak at Yosemite National Park (USA;
June–August 2012), which put an estimated 10,000 persons at risk of
infection and caused several fatal cases [6]. Transmission to humans
occurs through the respiratory tract by inhalation of dust and
aerosols containing virus-contaminated particles shed by persistently
infected viral reservoir species (primarily mice, voles and rats).
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So far, over 21 human pathogenic hantavirus serotypes have
been described [7–9], which are classified into New and Old
World hantaviruses according to their worldwide distribution and
genetic relatedness. New World hantaviruses include, amongst
various others, Andes virus (ANDV) [10] and Sin Nombre virus
(SNV) [11], the main causative agents of HCPS in South and
North America, respectively, with case-fatality rates of about 35%,
mainly due to pulmonary complications and cardiogenic shock
[12]. Clinically relevant Old World hantaviruses, predominately
distributed in the Eastern Hemisphere, include Dobrava (DOBV)
[13], Hantaan (HTNV) [14], Puumala (PUUV) [15], Seoul
(SEOV) [16] and Saaremaa (SAAV) virus [17,18]. The mildest
form of HFRS, designated nephropathia epidemica, is caused by
PUUV and is associated with a mortality rate of less than 0.1%.
SAAV also causes fairly mild HFRS, whereas SEOV, DOBV and
HTNV cause moderate to severe HFRS with fatality rates of 1–
15% [19].
Due to the rather unspecific symptoms such as headache,
backache, myalgia, shivering, abdominal pain and nausea in a
high proportion of infected patients, hantavirus syndromes are
often clinically misdiagnosed as influenza-like infections, renal
failure or idiopathic acute respiratory distress. In this context,
implementation of at least one laboratory test is mandatory to
support clinical diagnosis. Hantaviruses can be detected either
directly by virus isolation or reverse transcriptase polymerase
chain reaction (RT-PCR)-based amplification of hantaviral RNA
or indirectly by serology [20]. With respect to direct detection, it
has to be noted that the level of plasma-associated hantaviral RNA
rapidly decreases after the onset of initial symptoms and is
suggested to be associated with disease severity (highest RNA load
in patients with severe/critical disease) [21–23]. RT-PCR in
peripheral blood mononuclear cells (PBMC) yields a higher
sensitivity, and in most ANDV-infected patients it is successful for
up to 3 months after hospitalization (P.A. Vial, unpublished
results). Because of the short-termed viremia, detection of
hantavirus-specific serum antibodies of class IgM and IgG is most
reliable and, thus, widely used for confirmation of hantavirus
infection.
For the simultaneous detection of specific serum IgG and IgM
against the clinically important hantaviruses, multiparametric
indirect immunofluorescence assays (IFAs) were developed based
on mosaics of biochips coated with hantavirus-infected cells
(positive for serotypes HTNV, PUUV, SEOV, SAAV, DOBV,
SNV and ANDV). For assay evaluation, IgG and IgM antibodies
were determined in serum panels from healthy blood donors
(controls) and confirmed hantavirus-infected patients provided by
diagnostic laboratories in six different geographic regions. Previous
diagnostic data from these laboratories using mainly in-house or
sometimes commercial assays served as reference data.
Materials and Methods
Ethics statement
Samples tested were derived from already-existing collections at
the indicated institutes and were numerically coded, with the
identity of the persons available only to clinicians interacting with
the patients or blood donors. Furthermore, patient samples used in
this study were routine diagnostic samples taken with patient
consent and sent to the respective laboratory to be tested for anti-
hantavirus antibodies. Stored aliquots of these anonymized
samples were used in this study (conducted in the years 2006–
2009) for a comparison of diagnostic methodologies with each
sample being tested for the same parameter for which it had
initially been screened. The results were not accessible to any
outside body and were not reported to the donor or the patient.
Therefore written informed consent was not required. Samples
were included in this study on the basis of a statement from the
Central Ethics Committee of Germany on the use of human
samples for research studies [24].
Patients and serum samples
Assay evaluation was based on 5 serum panels comprising 184
samples from patients in the acute or convalescent phase of
hantavirus infection or with past hantavirus infection. Diagnosis of
infection was based on clinical (HFRS or HCPS) and serological
findings. Characteristics of infected patients are summarized in
Table 1. Panel V was a subset of the serum panel previously
analyzed by Schmidt and colleagues [25], including 23 sera from
Argentina (original sample IDs: 1A, 2A to 5A, 6A, 6B, 7B, 8B to
9B, 11 to 16, 18 to 20) and 29 sera from Chile (original sample
IDs: 1CH-A to 2CH-B, 3CH-A to 5CH-B, 6CH-A to 11CH,
13CH, 14CH, 16CH to 22CH). These sera were obtained from 38
patients (7 female, 31 male; median age 30 years; age range 8–77
years), including 13 follow-up patients. Data for gender and age of
the other individuals included in this study were not available. The
control group comprised 89 serum samples from apparently
healthy Canadian (n = 25) and German (n = 64) blood donors
(Table 1). All sera were stored at 280uC until analysis.
Serological reference assays
Laboratory confirmation of hantavirus infection was performed
at the indicated diagnostic centers shown in Table 1. Regarding
panel V, laboratory diagnosis had been performed at the WHO
Collaborating Centre for Arbovirus and Haemorrhagic Fever
Reference and Research (Hamburg, Germany). Reference tests
were characterized as follows (Table 1): panel I, IgG IFA based on
PUUV-infected Vero E6 cells, IgM m-capture ELISA based on
lysates of Sf9 insect cells expressing recombinant nucleocapsid (rN)
protein of PUUV [26]; panel II, IFA based on HTNV- or SEOV-
infected Vero E6 cells; panel III, IgM enzyme immunoassay (EIA)
Author Summary
Hantaviruses are the causative agents of hemorrhagic
fever with renal syndrome (HFRS) and hantavirus cardio-
pulmonary syndrome (HCPS) — serious emerging diseases,
with case-fatality rates of up to 15% and about 35%,
respectively. So far, over 21 human pathogenic serotypes
have been described, which are classified into New World
(circulating in the Americas) and Old World (Asia and
Europe) hantaviruses. The prodromal phase of hantavirus
infections — fever, myalgia, headache and gastrointestinal
symptoms — is indistinguishable from those of many
other viral infections. The cardiopulmonary phase of HFRS
and diuretic phase of HFRS mimic the acute respiratory
distress syndrome and renal failure, respectively. In this
context, clinical diagnosis has to be confirmed by
laboratory testing, which is predominantly based on
serology. Although there is an increasing awareness of
hantaviruses, infections are still underdiagnosed, in part
due to a lack of available standardized serological assays.
This study evaluated a commercial multiparametric indi-
rect immunofluorescence assay for the simultaneous
detection of antibodies against clinically important Old
World (Hantaan, Puumala, Seoul, Saaremaa and Dobrava)
and New World (Sin Nombre and Andes) hantaviruses. Test
performance was found to be comparable to established
highly sensitive and specific in-house assays.
Multiparametric IFA for Hantavirus Diagnostic
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based on rN protein (Dobrava-Hantaan IgM EIA from Reagena,
Toivala, Finland, and/or Hantavirus IgM EIA from Focus
Diagnostics, Cypress, USA) and rN-protein-based IgG EIA and/
or IgG ELISA (Hantavirus IgG EIA from Focus and/or
Hantavirus IgG ELISA from Progen, Heidelberg, Germany) or
IgG Western blot (recomBlot Bunyavirus IgG from Mikrogen,
Neuried, Germany); panel IV, IgG ELISA based on lysates from
Black Creek Canal virus (BCCV)-infected Vero E6 cells and IgM
capture ELISA based on antigen prepared from BCCV-infected
Vero E6 cells [27]; panel V, anti-ANDV ELISA based on yeast-
expressed rN protein of ANDV [25]. All patient samples were
positive for hantavirus-specific IgG and/or IgM in the corre-
sponding reference tests. In panel III, one follow-up serum from a
patient with past DOBV infection was previously tested for IgG
only, whereas in the present study both IgG and IgM were
determined by means of IFA. Reference tests used for examining
the control panel were: Anti-Hantavirus Pool 1 ‘‘Eurasia’’ ELISA
(IgG, IgM) based on recombinant nucleocapsid antigens of
HTNV, DOBV and PUUV; Anti-Hantavirus Pool 2 ‘‘America’’
ELISA (IgG, IgM) based on recombinant nucleocapsid antigens of
ANDV and SNV; anti-BCCV ELISA (IgG, IgM) as described
above.
Multiparametric immunofluorescence assays (IFAs)
For multiparametric IFA-based detection of hantavirus-specific
IgG and IgM, the Hantavirus Mosaic 1 and 3 (Euroimmun,
Luebeck, Germany; Fig. 1) were used. These assays are CE-
marked and validated according to Directive 98/79/EC on in
vitro diagnostic medical devices, fulfilling the requirements for
standardized and reproducible analyses. The IFAs are based on
millimeter-sized fragments of glass slides (biochips) glued side by
side on the reaction fields of a microscope slide. Biochips were
coated with hantavirus-infected EU14 cells, followed by acetone
fixation and gamma irradiation.
Table 1. Serum panels, clinical characteristics and serological assays.
Serum
panela Diagnostic center
No. of
samples
Clinical
characteristics
Hantavirus
serotype Reference test system
Multiparametric IFA
(Biochip mosaic
applied; Fig. 1)
I Department of Virology, Haartman
Institute, University of Helsinki (Finland)
97 HFRS Puumala (PUUV) Anti-PUUV ELISA (IgM)b
and Anti-PUUV IFA (IgG)c
Hantavirus Mosaic 1
II Department of Microbiology, Medical
Faculty, Chinese University of Hong
Kong (People’s Republic of China)
5 HFRS Seoul (SEOV) IFA (IgG and IgM)b Hantavirus Mosaic 1
III Laboratory of Vector-Borne Infections
and Medical Entomology, CANTACUZINO
National Institute for Research and
Development in Microbiology and
Immunology (Bucharest, Romania)
7 HFRS Dobrava (DOBV) EIA and/or ELISA (IgM)c
EIA/ELISA/WB (IgG)c
Hantavirus Mosaic 1
IV National Microbiology Laboratory, Health
Canada (Winnipeg, Canada)
23 HCPS Sin Nombre (SNDV) Anti-BCCV ELISA (IgG
and IgM)b
Hantavirus Mosaic 1
V Universidad del Desarrollo (Santiago,
Chile) and Hantavirus Laboratory,
National Institute of Infectious
Diseases (Buenos Aires, Argentina)
52 HCPS Andes (ANDV) Anti-ANDV ELISA (IgG
and IgM)b
Hantavirus Mosaic 1
and Hantavirus Mosaic
3
Control
sera
University Medical Center Schleswig-
Holstein (Luebeck, Germany)
64 Healthy - Anti-Hantavirus Pool 1
and 2 ELISA (IgG and IgM)c
Hantavirus Mosaic 1
and Hantavirus Mosaic
3
National Microbiology Laboratory,
Health Canada (Winnipeg, Canada)
25 Healthy - Anti-BCCV ELISA (IgG
and IgM)b
Hantavirus Mosaic 1
aPanel III included 7 sera from 3 follow-up patients and from a patient investigated once; one of the follow-up sera was tested only for IgG in the reference test; Panel V
included 25 single samples from 13 Argentinean and 12 Chilean patients as well as 27 serial samples from 13 follow-up patients (5 Argentinean and 8 Chilean) and was
tested on both Hantavirus Mosaic 1 and 3. Abbreviations: BCCV, Black Creek Canal virus; EIA, enzyme immunoassay; ELISA, enzyme-linked immunosorbent assay; HCPS,
hantavirus cardio-pulmonary syndrome; HFRS, hemorrhagic fever with renal syndrome; IFA, indirect immunofluorescence assay; WB, Western blot.
bIn-house assay.
cCommercial assay.
doi:10.1371/journal.pntd.0002157.t001
Figure 1. Immunofluorescence microscope slides for the
multiparametric detection of hantavirus-specific antibodies. A
microscope slide has ten reaction fields, each of which contains a
biochip mosaic, allowing ten samples or sample dilutions to be
incubated simultaneously with the same range of substrates. Due to
identical incubation protocols, IgG and IgM testing can be performed
on different reactions fields of the same slide using the respective
secondary antibody conjugate. Hantavirus Mosaic 1 comprises mosaics
of six biochips coated with Hantaan virus (HTNV)-, Puumala virus
(PUUV)-, Seoul virus (SEOV)-, Sin Nombre virus (SNV)-, Dobrava virus
(DOBV)- and Saaremaa virus (SAAV)-infected cells (-IC). Hantavirus
Mosaic 3 consists of mosaics of two biochips coated with Sin Nombre
virus (SNV)- and Andes virus (ANDV)-IC.
doi:10.1371/journal.pntd.0002157.g001
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For standardized testing, the TITERPLANE Technique
(Euroimmun) was applied at room temperature according to the
manufacturer’s instructions. In brief, serial tenfold dilutions (1:10
to 1:10,000) of blinded sera were prepared in sample buffer
(Euroimmun). For class IgM antibody determination, serum IgG
and rheumatoid factors were first preabsorbed by diluting sera
1:10 in EUROSORB (Euroimmun), mixing thoroughly and
incubating for 15 min. After centrifugation (5 min, 2,000 rpm)
the supernatant was diluted serially as described above. Samples
were applied to the reaction fields of a reagent tray. Mosaic-
containing slides were placed into the corresponding recesses of
the reagent tray, where all substrates came into contact with the
fluids, and the individual reactions commenced simultaneously.
After incubation for 30 min, slides were rinsed with a flush of PBS-
Tween (PBS containing 0.2% Tween-20) and immersed in PBS-
Tween for 5 min. For detection of bound antibodies, slides were
placed on reagent trays prepared with fluorescein isothiocyanate
(FITC)-conjugated goat anti-human immunoglobulin. To test for
IgG antibodies, the respective reaction fields were loaded with the
anti-human-IgG FITC conjugate. Accordingly, the anti-human-
IgM FITC conjugate was applied to those reaction fields intended
for the detection of IgM. Following a 30-min incubation, slides
were washed as described above, embedded with mounting
medium, coverslipped and evaluated by fluorescence microscopy.
Evaluation was performed independently by at least two
experienced laboratory experts without reference to the clinical
diagnosis and serological precharacterization data. Positive reac-
tions were characterized by a fine- to coarse-granular immuno-
fluorescence (IF) in the cytoplasm of infected cells. Intensities of
specific IF were compared to those of hantavirus-negative and -
positive reference sera and scored as negative, weak, moderate or
strong. Antibody titers were determined based on the 10-fold
dilution series, allowing for assumed intermediate titers (corre-
sponding to a theoretical dilution factor of 3.2). Samples with at
least a weak specific IF at a dilution of 1:100 (cut-off) were
considered positive. The reciprocal endpoint titer was defined as
the highest sample dilution factor for which a weak specific IF was
detected. For example, if a serum showed a strong IF at a dilution
of 1:10 and 1:100, a moderate IF at 1:1,000 and a negative IF at
1:10,000, it was assigned a reciprocal endpoint titer of 3,200. If
another serum showed a strong IF at 1:10 and 1:100, but only a
weak IF at 1:1,000 and negative IF at 1:10,000, the reciprocal
endpoint titer was 1,000. The groups’ reciprocal geometric mean
titers (rGMT) were determined using Excel (Microsoft, Redmond,
USA). In a group of n samples, the rGMT was calculated as the
nth root of the product of the samples’ reciprocal endpoint titers.
Results
Performance of multiparametric anti-hantavirus IFAs
The overall qualitative performance of multiparametric IFAs in
detecting anti-hantavirus antibodies was analyzed by considering
those samples as seropositive that showed specific reactivity (cut-off
1:100) against at least one of the different hantavirus serotypes
contained in the biochip mosaics.
As shown in Table 2, the overall agreement between the
reference tests and multiparametric IFAs was 96% for IgG and
93% for IgM analysis in the patient sera. Multiparametric IFA-
based combined IgG and IgM analyses revealed 100% sensitivity
for all serum panels, except for panel IV (96%). With respect to the
control cohort, none of the healthy blood donors was antibody
positive by the reference tests, whereas 2/89 (2%) were IgG
positive for HTNV by IFA (98% specificity).
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In detail, among a total of 184 hantavirus-positive sera, 177
(96%) and 183 (99%) were IgG positive in the reference tests and
IFA, respectively. All samples of panels I, II and III were anti-
hantavirus IgG positive by precharacterization and multipara-
metric IFA. In panel IV, 20/23 (87%) Canadian HCPS patients
had hantavirus-specific IgG according to the ELISA-based
precharacterization, while the multiparametric IFA revealed a
higher positivity rate of 96% (22/23). Discrepant IgG results were
found in 4/23 (17%) samples of this panel, including 3 ELISA IgG
negative/IFA IgG positive sera that were obtained during acute
SNV infection and were confirmed by RT-PCR (Table 3; sera
#CA-22, #CA-23 and #CA-24). Another serum (#CA-12) was
ELISA IgG positive/IFA IgG negative. In panel V, the IgG IFA
achieved a higher seropositivity rate (52/52, 100%) than the
reference test (48/52, 92%). The 4 sera of this panel that were
ELISA IgG negative/IFA IgG positive had been drawn during
acute infection, i.e. within 3 to 5 days after onset of initial
symptoms (Table 3; sera #2B, #13, #18 and #19).
According to the reference tests, 131 (72%) patient sera were
IgM positive, referring to a total of 183 sera with IgM
precharacterization. Using IFA, 131 (71%) out of all 184 patient
samples tested IgM positive. Comparing the performance within
each serum panel, IgM positivity rates were equal in panel II
(reference test/IFA, 100%/100%), but different in panel I (54%/
56%), panel III (83%/71%), panel IV (74%/83%) and panel V
(100%/92%). Discordant results were obtained for 13 (7%) of the
patient sera, for 7 of which IgM-positivity by precharacterization
contrasted with IgM-negativity by IFA. However, 5 of them had
been drawn in the convalescent phase of the disease (Table 3;
panel III, #RO-7; panel V, #1A, #3A, #3B and #6B). Serum
#6B derived from a follow-up patient whose first serum sample
(#6A), drawn 16 days after onset of symptoms, was IgM positive
in the IFA. The remaining 6 sera with discordant IgM results were
negative in the reference tests but positive in the multiparametric
IFA (Table 3).
When restricting the evaluation to only the (endemic) serotype-
specific substrate, a subset of IFA positive sera (5/184, 3%) was
either IgM or IgG negative, indicating the possibility of
misdiagnosis when serological screening is limited to the suspected
(endemic) serotype. Among these 5 cases, 2 sera from PUUV-
infected patients (panel I) showed IgM reactivity on the HTNV
substrate only, 2 sera from Canadian SNV-infected patients (panel
IV) showed IgG/IgM reactivity on the PUUV substrate only,
while the remaining serum from a SEOV-infected Chinese patient
(panel II) showed IgM reactivity to HTNV only.
Multiparametric IFA-based hantavirus serotyping
Depending on the causative hantavirus, cross-reactivity rates of
up to 100% were observed when comparing reactivity rates
between the seven serotypes used as IFA substrates (Fig. 2 A and
C). In general, reciprocal geometric mean titers (rGMTs) of anti-
hantavirus IgM were lower than IgG rGMTs (Fig. 2 B and D).
In panel I, all (100%) IFA IgG positive and 96% of the IFA IgM
positive sera reacted on PUUV-infected cells (IC), with rGMTs of
2,530 (IgG) and 347 (IgM). Positivity rates of serum IgG/IgM
from PUUV-infected patients were also high on SNV-IC (86%/
75%) and HTNV-IC (79%/49%), but only moderate (IgG, 53–
57%) or low (IgM, 6–15%) on SEOV-, SAAV- and DOBV-IC.
Table 3. Serum samples with discordant results between the reference tests and the multiparametric immunofluorescence assay
(IFA).
Serum panel Discordant sera (Sample ID) Time of sampling (Days after onset)a Reference test (IgG/IgM) IFA (IgG/IgM)
I–PUUV (n = 97) FI-21 NA +/+ +/2
FI-24 NA +/2 +/+
FI-38 NA +/2 +/+
FI-55 NA +/2 +/+
III–DOBV (n = 7) RO-7 .60d +/+ +/2
IV–SNV (n = 23) CA-01 NA +/+ +/2
CA-12 NA +/2 2/2
CA-15 NAb +/2 +/+
CA-16 NA +/2 +/+
CA-17 NA +/2 +/+
CA-22 NAb 2/+ +/+
CA-23 NAb 2/+ +/+
CA-24 NAb 2/+ +/+
V–ANDV (n = 52) 2B 3d 2/+ +/+
13 4d 2/+ +/+
18 4d 2/+ +/+
19 5d 2/+ +/+
3A 213d +/+ +/2
6B 31d +/+ +/2
1A 395d +/+ +/2
3B 335d +/+ +/2
aDays after onset of initial symptoms; NA, data not available.
bHantavirus infection was confirmed by Western blot and neutralization test (#CA-15) or by RT-PCR (#CA-22 to #CA-24).
doi:10.1371/journal.pntd.0002157.t003
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Sera from SEOV-infected patients (panel II) were IgG positive
on all tested substrates, while serum IgM revealed highest
reactivity (100%) on HTNV-IC. On SEOV- and HTNV-IC,
rGMTs of IgG were identical (10,000) or higher compared to
those on the other substrates (,4,000); rGMTs of IgM were
highest on HTNV-IC (251), followed by SEOV- and SAAV-IC
(158).
In accordance with the phylogenetic relatedness of hantaviruses,
the highest positivity rates of sera from DOBV-positive patients
(panel III) were found on DOBV-, SAAV-, HTNV- and SEOV-
IC (IgG/IgM, 100%/60–100%), and markedly lower on PUUV-
and SNV-IC (#43%). The rGMTs of IgG and IgM were highest
on HTNV-IC (22,952) and DOBV-IC (1,005), respectively.
Among all hantavirus-infected patients, SNV infections (panel
IV) were associated with the lowest serotype-specific rGMTs of
198 (IgG) and 138 (IgM). Serum IgG/IgM from SNV-infected
patients reacted on SNV-IC (95%/95%), PUUV-IC (55%/42%)
and HTNV-IC (5%/5%), whereas SEOV-, SAAV- and DOBV-
IC were negative. These samples were not available for testing on
ANDV-IC, but considering the antigenic relatedness of SNV and
ANDV, a significant degree of cross-reactivity can be expected,
similar to the results obtained for ANDV-infected patients’ sera on
SNV-IC.
For ANDV-positive sera (panel V), the highest reactivity rates
(100%) and rGMTs (IgG/IgM, 13,999/5,389) were detected on
ANDV-IC. Slightly less reactivity (98%/83%) and lower rGMTs
(1,166/976) were observed on SNV-IC.
Accordingly, serotyping by endpoint titration was successful in
the majority of ANDV-infected patients (Fig. 3, panel V), when
IgG titers were evaluated separately (77%) or in conjunction with
IgM (96%). Regarding panel I, PUUV could be serotyped in
87% and 91% of patients by IgG antibody titration and by
combined IgG and IgM analysis, respectively. In panel II and
III, a clear serotype could be determined in only a minority of
cases due to the high cross-reactivity rates. In panel IV, IgG plus
IgM analysis revealed a clear serotype in 58% of the patients; the
remaining sera reacted equally on SNV- and PUUV-IC, but
SNV could be assigned as the causative agent due to its
distribution in North America and the absence of PUUV on the
American continent.
Figure 2. Multiparametric IFA-based reactivity patterns of hantavirus-specific serum antibodies. Bars indicate reactivity rates or
reciprocal geometric mean titers (rGMT) for IFA IgG positive sera (A and B; serum panel: I, n = 97; II, n = 5; III, n = 7; IV, n = 22; V, n = 52) and IFA IgM-
positive sera (C and D; serum panel: I, n = 54; II, n = 5; III, n = 5; IV, n = 19; V, n = 48) for each substrate (cells infected with HTNV, PUUV, SEOV, SAAV,
DOBV, SNV and ANDV). Dashed horizontal lines (right panels) indicate the reciprocal cut-off titer; black triangles indicate reactivity rates of 0% (left
panels) or rGMTs of ,10 (lower right panel). Results for panel IV with ANDV-infected cells were not available.
doi:10.1371/journal.pntd.0002157.g002
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Discussion
Due to the nonspecific clinical symptoms associated with the
majority of hantavirus infections, confirmatory laboratory diagnosis
is crucial. Generally, acute hantavirus infections are diagnosed
serologically by determination of an at least four-fold increase in the
IgG titer in consecutive serum samples and/or detection of specific
IgM. In-house enzyme-linked immunosorbent assays (ELISAs) and
indirect immunofluorescence assays (IFAs) based on antigen from a
single or two hantavirus serotypes are widely used for this purpose
[28], although these assays may not allow standardized testing of
consistently high quality. Furthermore, considering the fact that
hantavirus serotypes co-circulate in parts of Europe (PUUV, DOBV
and SAAV; [29,30]), Russia (SAAV, PUUV, DOBV and HTNV;
[31]) and Asia (HTNV, SEOV and PUUV; [32,33]), monospecific
tests may fail to detect the causative agent of hantavirus infection,
despite the high cross-reactivity rates between closely related
hantaviruses [34]. Between the different hantaviruses there are
extensive antigenic/serological cross-reactivities that closely follow
the phylogenic tree [20]. Thus, the cross-reactivities are especially
strong within each group (Murinae-borne, Arvicolinae-borne,
Sigmodontinae-borne, Neotominae-borne).
In this study the diagnostic performance of commercial
multiparametric hantavirus IFAs based on mosaics of biochips
coated with seven different hantavirus-infected cell substrates was
evaluated and compared with results from previous laboratory
testing using in-house or commercial assays. Among the reference
tests were ELISAs using recombinant hantavirus nucleoprotein
(rN) as antigen substrate. The N protein represents the major
hantavirus antigen and induces an early, strong and long-lasting
antibody response [35–38]. Recombinant N protein-based assays
have been reported to show high sensitivity for hantavirus-specific
IgG and IgM [39,40].
To evaluate the sensitivity and specificity of multiparametric
hantavirus IFAs, five laboratory-confirmed hantavirus-positive
serum panels obtained from six diagnostic centers located in
different geographic regions were used. Multiparametric IFA-
based determination of hantavirus-specific IgM and IgG yielded
an excellent diagnostic sensitivity of 100% for all panels, except for
panel IV (96%). The IFA total seropositivity rate for IgG detection
(99%) exceeded that of the reference tests (96%), with an overall
agreement of 96%. With respect to the control group, none of the
25 Canadian but 2/64 German healthy blood donors tested IgG
positive on the HTNV-IC at the cut-off dilution of 1:100. These
two samples tested negative on the SEOV-, DOBV- and SAAV-
IC IFA substrates. Both an anti-hantavirus ELISA and an anti-
hantavirus lineblot based on nucleocapsid antigen from PUUV,
DOBV, HTNV, SEOV, SNV and ANDV (Euroimmun) were
negative, too. Therefore unspecific (false-positive) reactions cannot
be ruled out. In the absence of clinical symptoms and without
travel history to HTNV endemic regions, such borderline and
isolated reactivities on HTNV-IC should be considered as
unspecific.
The seropositivity rate of IgM detection by IFA (71%) was
almost the same as by the reference methods (72%). However,
there was only 93% agreement between the methods, and 13 sera
showed discordant IgM results. Among these discordant cases, 7
serum samples had IgM positive reference data, but tested IgM
negative by IFA. Five of these sera were drawn in the convalescent
phase of a hantavirus infection, namely 1, 7, 11 and 13 months
(ANDV-infected patients) and more than 2 months (DOBV-
infected patient) after the onset of initial symptoms. Consequently,
four of these probably contained persisting IgM antibodies against
hantaviral rN protein, since hantavirus-specific IgM usually
disappears two to three months after the onset of symptoms
[41]. Persistence of IgM antibodies against hantaviral rN protein
for as long as two to three years after hospitalization has been
reported previously in DOBV-infected patients [42].
With respect to hantavirus-specific IgG, persistence over many
years or even life-long may occur, and the IgG response can be
Figure 3. Hantavirus serotype determination by multiparametric indirect immunofluorescence analysis. For sera which were IFA
positive for both anti-hantavirus IgG and IgM (serum panel: I, n = 54; II, n = 5; III, n = 5; IV, n = 19; V, n = 48), percentages of hantavirus serotypes with
the highest reciprocal IgG endpoint titers were calculated (left bars). Right bars represent results of serotyping by IgG in conjunction with IgM
detection. For serum panels I and V, only those serotypes which accounted for more than 2% of the total number of sera are indicated. Results for
panel IV with ANDV-infected cells were not available.
doi:10.1371/journal.pntd.0002157.g003
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delayed in some patients. In the multiparametric IFA, none of the
184 samples was isolated IgM-positive, whereas ELISA-based
analysis of sera from SNV-infected patients revealed 3/23 (13%)
isolated IgM-positive results. This finding corresponds with recent
studies, demonstrating that SNV-specific IgM occurs early after
infection, whereas anti-SNV IgG is not detectable in a sizable
proportion of sera drawn in the early acute phase [34,43].
Furthermore, in four sera obtained from ANDV-infected patients
3 to 5 days after onset of initial symptoms, isolated IgM was
detected by the ANDV rN protein-based reference ELISA [25].
These discordant IFA/ELISA IgG results could be explained by
an earlier appearance of IgG antibodies against hantavirus
glycoprotein Gn (formerly termed G1) compared to anti-N protein
antibodies as observed previously in acute phase sera [36]. Our
data suggest that IgG seroconversion from negative to positive as
well as IgM seroconversion from positive to negative is detected
earlier by whole native antigen (presented in the IFA) than by
recombinant N protein (presented in the ELISA). Considering the
need for IgM confirmation by IgG seropositivity, isolated IgM
results involve sampling and analysis of at least one consecutive
serum sample. Regarding the higher IFA IgG sensitivity,
heterogeneous antigen seems to be at least as suited as
homogenous antigen to screening for anti-hantavirus IgG in
patients suspected of having hantavirus infection.
Notably, multiparametric IFA analysis improved the diagnostic
sensitivity, since three samples precharacterized as positive for
anti-SEOV IgM and anti-SNV IgM or IgG were found to be only
positive on cells infected with closely related hantaviruses (HTNV
and PUUV, respectively). This reflects the cross-reacting ability of
hantavirus-specific antibodies, which is particularly strong for
antibodies against the highly conserved N protein [44–49]. As a
consequence, serological identification of the causative hantavirus
in areas with co-existing serotypes is difficult. Reliable serotyping is
particularly important, because severity of syndromes depends on
the causative hantavirus serotype [9]. The gold standard for
hantavirus serotyping is the neutralization test [50–52], which is
most reliable but laborious, time-consuming and expensive and
has to be performed in a containment laboratory (BSL-3).
Serotyping ELISA based on truncated N-proteins have been
developed [53–55], but can be used as second line diagnostics
only, due to a reduced sensitivity. In our study, serotyping by IgG
in conjunction with IgM IFA analysis was successful in the
majority of HCPS patients infected with ANDV (96%) and HFRS
patients infected with PUUV (91%), representing a fast and simple
alternative to more elaborate methods. Serotyping failed in
patients infected with murinae-borne Old World hantaviruses
(DOBV and SEOV), because of their close phylogenetic related-
ness with HTNV and SAAV: DOBV N protein has an amino acid
sequence identity of 99%, 83% and 80% with the N protein of
SAAV, HTNV and SEOV, respectively. Here only neutralization
tests or serotyping ELISA can reliably distinguish antibodies raised
against these serotypes. However, with respect to the different
geographical distribution of HTNV (predominantly South Korea/
China/Russia) and DOBV (Balkans) [7], multiparametric IFA-
based serotyping in combination with the patient’s travel history
and clinical characteristics is possible in many cases. For example,
in the Romanian hantavirus-infected patients with severe HFRS
and without travel history, an infection with HTNV could be
excluded, revealing DOBV or SAAV as the causative agent.
Infection with SAAV, circulating in Estonia, Finland, Germany,
Hungary, Lithuania, Russia, Slovenia and Slovakia [56], could be
further excluded because it is associated with milder symptoms.
The worldwide increasing number of hantavirus infection
demonstrates the need for reliable serological tests which are
simple to perform and allow detection of all clinically relevant
hantaviruses. Many hantavirus-infected patients are still misdiag-
nosed [57–61], often due to the lack of generally available
standardized assays and of epidemiological data. In line with the
most recent European external quality assurance study for
hantavirus diagnosis [62], the present study revealed similar
performance of IFA and ELISA/EIA. In contrast to the
homogenous antigen-presenting ELISA/EIA, the mosaic-based
IFA evaluated in this study provides multiparametric testing by
combining different substrates of cells infected with clinically
relevant Old and New World hantaviruses. Furthermore, unlike
in-house IFAs, this commercial assay does not depend on cell
culture (establishment of infected cells) and propagation of
hantaviruses, since large batches of identical infected cells were
created and stored in liquid nitrogen, allowing standardization of
immunological analyses. This makes hantavirus testing more
widely available to all laboratories familiar with IFA-based
diagnostics. In conclusion, analysis of hantavirus-specific IgG
and IgM by indirect immunofluorescence on substrate mosaics
consisting of cells infected with different hantaviruses is a globally
applicable and reliable diagnostic tool for screening of patients
suspected of having hantavirus infection, and can be useful for
serotyping in areas where hantaviruses of different serogroups are
endemic.
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